Targeting CBP and p300: Emerging Anticancer Agents

Area of Science:

• Molecular Biology
• Cancer Research
• Drug Discovery

Background:

• CBP and p300 are key transcriptional co-activators regulating vital cellular processes and signaling pathways like Wnt/β-catenin.
• Dysregulated Wnt/β-catenin signaling is implicated in various cancers, driving tumor proliferation, migration, and invasion.
• Targeting the interaction between β-catenin and CBP/p300 presents a promising strategy for cancer therapy.

Purpose of the Study:

• To review recent advancements (2010-present) in developing small molecule inhibitors targeting CBP/β-catenin and p300/β-catenin interactions.
• To explore the therapeutic potential of CBP/p300 bromodomain and histone acetyltransferase inhibitors in cancer treatment.
• To provide an overview of strategies targeting CBP and p300 in Wnt/β-catenin-driven oncogenesis.

Main Methods:

• PubMed literature search for original research articles from 2010 to date.
• Focus on studies developing specific and non-specific inhibitors of CBP/β-catenin and p300/β-catenin interactions.
• Inclusion of research on CBP/p300 bromodomain and histone acetyltransferase inhibitors.

Main Results:

• Significant progress has been made in identifying small molecules that inhibit CBP/β-catenin and p300/β-catenin interactions.
• Various CBP/p300 inhibitors show therapeutic potential by disrupting oncogenic signaling pathways.
• Research highlights the role of these co-activators in Wnt/β-catenin-driven cancers.

Conclusions:

• Targeting CBP and p300 interactions with β-catenin offers a viable therapeutic approach for Wnt/β-catenin-driven cancers.
• CBP/p300 inhibitors, including bromodomain and HAT inhibitors, represent a promising avenue for novel cancer treatments.
• Further research into these targeted therapies is crucial for effective cancer intervention.